<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03710889</url>
  </required_header>
  <id_info>
    <org_study_id>BA058-05-020</org_study_id>
    <nct_id>NCT03710889</nct_id>
  </id_info>
  <brief_title>Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption</brief_title>
  <official_title>An Open-Label, Single-Arm, Multicenter Study to Evaluate the Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radius Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radius Health, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to measure the early effects of abaloparatide on tissue-based&#xD;
      bone formation using samples obtained by transiliac crest bone biopsy after quadruple&#xD;
      fluorochrome labeling.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an open-label, single-arm study of postmenopausal women with osteoporosis treated&#xD;
      with 80 micrograms (μg) abaloparatide for 3 months. Transiliac bone biopsies were taken at 3&#xD;
      months after quadruple fluorochrome labeling. The treatment duration of 3 months was&#xD;
      determined to be the optimal time when biochemical markers of bone turnover peak and are&#xD;
      predictive of subsequent changes in bone mineral density (BMD).&#xD;
&#xD;
      The main study was conducted for a 3-month treatment period with a 1-month follow up. A&#xD;
      sub-study was conducted at 1 site to collect peripheral quantitative computed tomography&#xD;
      (pQCT) data. Study treatment for participants in the sub-study was extended for an additional&#xD;
      3 months of study drug administration for a total of 6 months of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 20, 2018</start_date>
  <completion_date type="Actual">July 15, 2020</completion_date>
  <primary_completion_date type="Actual">July 15, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Envelope at Month 3</measure>
    <time_frame>Baseline (Day 1), Month 3</time_frame>
    <description>Change in dynamic histomorphometry indices was assessed in the cancellous envelope.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Bone Formation Rate/Bone Surface (BFR/BS) in the Cancellous Envelope at Month 3</measure>
    <time_frame>Baseline (Day 1), Month 3</time_frame>
    <description>Change in dynamic histomorphometry indices was assessed in the cancellous envelope. BFR/BS was reported as cubic millimeter/square millimeter/year (mm^3/mm^2/year).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Procollagen Type I N-terminal Propeptide (s-P1NP) From Baseline at Month 1 and Month 3</measure>
    <time_frame>Baseline (Day 1), Months 1 and 3</time_frame>
    <description>Blood samples were taken to measure efficacy related markers of bone metabolism at Day 1, Month 1, and Month 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Carboxy-Terminal Cross-Linking Telopeptide of Type I Collagen (s-CTX) From Baseline at Month 1 and Month 3</measure>
    <time_frame>Baseline (Day 1), Months 1 and 3</time_frame>
    <description>Blood samples were taken to measure efficacy-related markers of bone metabolism at Day 1, Month 1, and Month 3.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Osteoporosis, Postmenopausal</condition>
  <condition>Osteoporosis</condition>
  <condition>Osteoporosis Vertebral</condition>
  <condition>Osteoporosis Risk</condition>
  <condition>Osteoporosis Fracture</condition>
  <condition>Osteoporosis Localized to Spine</condition>
  <condition>Osteoporosis, Age-Related</condition>
  <condition>Osteoporosis Senile</condition>
  <condition>Osteoporosis of Vertebrae</condition>
  <arm_group>
    <arm_group_label>Abaloparatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants self-administered a single daily dose of 80 micrograms (µg) of abaloparatide subcutaneously (SC) during the treatment period. Participants were instructed to use a new injection pen after each 30-day period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abaloparatide</intervention_name>
    <description>Abaloparatide is a novel, synthetic, 34 amino acid peptide designed to be a potent and selective activator of the PTH/PTH-related protein (PTHrP) type 1 receptor (PTHR1) signaling pathway with 41% homology to PTH[1-34] and 76% homology to human PTHrP[1-34].</description>
    <arm_group_label>Abaloparatide</arm_group_label>
    <other_name>TYMLOS®</other_name>
    <other_name>BA058</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Participants must meet all of the following criteria to be eligible to participate in this&#xD;
        study:&#xD;
&#xD;
          1. The participant is a healthy ambulatory postmenopausal female from 50 to 85 years of&#xD;
             age (inclusive) with osteoporosis.&#xD;
&#xD;
          2. The participant has been postmenopausal for at least 5 years. Postmenopausal status&#xD;
             will be established by a history of amenorrhea for at least 5 years and by an elevated&#xD;
             follicle stimulating hormone (FSH) value of ≥30 international units(IU)/liter (L).&#xD;
&#xD;
          3. The participant has a BMD T-score ≤-2.5 at the lumbar spine (L1-L4) or hip (femoral&#xD;
             neck or total hip) by dual-energy x-ray absorptiometry (DXA) or lumbar spine or hip&#xD;
             BMD T-score ≤-2.0 with a history of low trauma vertebral, forearm, humerus, sacral,&#xD;
             pelvic, hip, femoral, or tibial fracture sustained within 5 years prior to enrollment.&#xD;
             These fractures must be documented by radiograph or hospital report.&#xD;
&#xD;
          4. The participant is in good general health as determined by medical history and&#xD;
             physical examination (including vital signs), has a body mass index (BMI) of 18.5 to&#xD;
             33, inclusive, and is without evidence of clinically significant abnormality in the&#xD;
             opinion of the Investigator.&#xD;
&#xD;
          5. The participant has serum calcium (albumin-corrected), parathyroid hormone (PTH)&#xD;
             (1-84), phosphorus, and alkaline phosphatase levels all within the normal range during&#xD;
             the Screening Period. Any participant with an elevated alkaline phosphatase value, and&#xD;
             who meets all other entry criteria, is required to have a normal bone-specific&#xD;
             alkaline phosphatase result to be enrolled.&#xD;
&#xD;
          6. The participant has serum 25-hydroxyvitamin D values ≥ 20 nanograms (ng)/milliliter&#xD;
             (mL) and within the normal range. Participants with serum 25-hydroxyvitamin D levels &lt;&#xD;
             20 ng/ml may be treated with vitamin D3 and re-tested once.&#xD;
&#xD;
          7. The participant's resting 12-lead electrocardiogram (ECG) obtained during screening&#xD;
             shows no clinically significant abnormality.&#xD;
&#xD;
          8. The participant has read, understood, and signed the written informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants with any of the following characteristics are not eligible to participate in&#xD;
        the study:&#xD;
&#xD;
          1. Presence of abnormalities of the lumbar spine that would prohibit assessment of lumbar&#xD;
             spine BMD, defined as having at least 2 radiologically evaluable vertebrae within&#xD;
             L1-L4.&#xD;
&#xD;
          2. Unevaluable hip BMD or participants who have undergone bilateral hip replacement&#xD;
             (unilateral hip replacement is acceptable).&#xD;
&#xD;
          3. History of bone disorders (for example, Paget's disease) other than postmenopausal&#xD;
             osteoporosis.&#xD;
&#xD;
          4. Clinically significant abnormality of serum hemoglobin, hematocrit, white blood cells&#xD;
             (WBC) and platelets, coagulation, or usual serum chemistry: electrolytes, renal&#xD;
             function, liver function and serum proteins.&#xD;
&#xD;
          5. Unexplained elevation of serum alkaline phosphatase.&#xD;
&#xD;
          6. History of radiotherapy (radiation therapy), other than radioiodine.&#xD;
&#xD;
          7. History of bleeding disorder that would preclude a bone biopsy, in the opinion of the&#xD;
             Investigator.&#xD;
&#xD;
          8. History of chronic or recurrent renal, hepatic, pulmonary, allergic, cardiovascular,&#xD;
             gastrointestinal, endocrine, central nervous system, hematologic or metabolic&#xD;
             diseases, or immunologic, emotional and/or psychiatric disturbances to a degree that&#xD;
             would interfere with the interpretation of study data or compromise the safety of the&#xD;
             participant.&#xD;
&#xD;
          9. History of Cushing's disease, hyperthyroidism, hypo- or hyperparathyroidism, or&#xD;
             malabsorptive syndromes within the past year.&#xD;
&#xD;
         10. History of significantly impaired renal function (serum creatinine &gt; 177 micromoles&#xD;
             [µmol]/L or &gt;2.0 milligrams [mg]/deciliter [dL]). If the serum creatinine is &gt;1.5 and&#xD;
             ≤ 2.0 mg/dL, the calculated creatinine clearance (Cockcroft-Gault) must be ≥ 30&#xD;
             mL/minute (min).&#xD;
&#xD;
         11. History of any cancer within the past 5 years (other than basal cell or squamous cell&#xD;
             cancer of the skin).&#xD;
&#xD;
         12. History of osteosarcoma at any time or a history of hereditary disorders which could&#xD;
             predispose the participant to osteosarcoma.&#xD;
&#xD;
         13. History of nephrolithiasis or urolithiasis within the past 5 years.&#xD;
&#xD;
         14. Participant known to be positive for hepatitis B, hepatitis C, or human&#xD;
             immunodeficiency virus infection (HIV-1 or HIV-2). Testing is not required in the&#xD;
             absence of clinical signs and symptoms suggestive of HIV infection or acute or chronic&#xD;
             hepatitis.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Radius Health, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Panorama Orthopedics &amp; Spine Center</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Advanced Research &amp; Education</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harvard Medical School</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ. Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling. Endocrinology. 2016 Jan;157(1):141-9. doi: 10.1210/en.2015-1726. Epub 2015 Nov 12.</citation>
    <PMID>26562265</PMID>
  </reference>
  <reference>
    <citation>Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Valter I, Fitzpatrick LA, Riis BJ, Christiansen C, Bilezikian JP, Black D. Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial. Mayo Clin Proc. 2017 Feb;92(2):200-210. doi: 10.1016/j.mayocp.2016.10.009.</citation>
    <PMID>28160873</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 15, 2018</study_first_submitted>
  <study_first_submitted_qc>October 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2018</study_first_posted>
  <results_first_submitted>September 5, 2021</results_first_submitted>
  <results_first_submitted_qc>October 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 15, 2021</results_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BA058</keyword>
  <keyword>abaloparatide</keyword>
  <keyword>TYMLOS®</keyword>
  <keyword>Bone metabolism</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Fracture</keyword>
  <keyword>Bone loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
    <mesh_term>Osteoporotic Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abaloparatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT03710889/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 5, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT03710889/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Abaloparatide</title>
          <description>Participants self-administered a single daily dose of 80 micrograms (µg) of abaloparatide subcutaneously (SC) during the treatment period. Participants were instructed to use a new injection pen after each 30-day period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Bone-Biopsy Population</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Abaloparatide</title>
          <description>Participants self-administered a single daily dose of 80 µg of abaloparatide SC during the treatment period. Participants were instructed to use a new injection pen after each 30-day period.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.4" spread="8.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kilogram (kg)/square meter (m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.92" spread="3.629"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lumbar Spine Bone Mineral Density (BMD) T-Scores</title>
          <description>At Baseline, participants were required to have a BMD T-score ≤-2.5 by dual-energy x-ray absorptiometry (DXA) or BMD T-score ≤-2.0 with a history of low trauma vertebral, forearm, humerus, sacral, pelvic, hip, femoral, or tibial fracture sustained within 5 years prior to enrollment. Osteoporosis status was based on the World Health Organization (WHO) 2007 criteria of normal (T-score &gt;-1.0), osteopenia (T-score &gt;-2.5 to ≤-1.0), and osteoporosis (T-score ≤-2.5).</description>
          <units>T-Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Total Hip BMD T-Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-2.392" spread="0.6363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femoral Neck BMD T-Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-2.530" spread="0.5708"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumbar Spine BMD T-Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-2.232" spread="1.3098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Envelope at Month 3</title>
        <description>Change in dynamic histomorphometry indices was assessed in the cancellous envelope.</description>
        <time_frame>Baseline (Day 1), Month 3</time_frame>
        <population>The Bone-Biopsy Population included all participants who received an evaluable biopsy (defined as a biopsy sample that can be analyzed in the laboratory). Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Abaloparatide</title>
            <description>Participants self-administered a single daily dose of 80 µg of abaloparatide SC during the treatment period. Participants were instructed to use a new injection pen after each 30-day period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Envelope at Month 3</title>
          <description>Change in dynamic histomorphometry indices was assessed in the cancellous envelope.</description>
          <population>The Bone-Biopsy Population included all participants who received an evaluable biopsy (defined as a biopsy sample that can be analyzed in the laboratory). Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
          <units>percentage of MS/BS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.74" spread="3.978"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.66" spread="12.114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Within treatment paired t-tests were used to compare the differences in dynamic indices between Baseline and Month 3 using the Bone-Biopsy Population. If the normality assumption is not satisfied at the 0.01 significance level and visual inspection of the data deems it necessary, Wilcoxon signed-rank test is used. No adjustments for multiplicity were made. A 2-sided p-value &lt;0.05 was considered statistically significant.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Paired t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Bone Formation Rate/Bone Surface (BFR/BS) in the Cancellous Envelope at Month 3</title>
        <description>Change in dynamic histomorphometry indices was assessed in the cancellous envelope. BFR/BS was reported as cubic millimeter/square millimeter/year (mm^3/mm^2/year).</description>
        <time_frame>Baseline (Day 1), Month 3</time_frame>
        <population>The Bone-Biopsy Population included all participants who received an evaluable biopsy (defined as a biopsy sample that can be analyzed in the laboratory). Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Abaloparatide</title>
            <description>Participants self-administered a single daily dose of 80 µg of abaloparatide SC during the treatment period. Participants were instructed to use a new injection pen after each 30-day period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bone Formation Rate/Bone Surface (BFR/BS) in the Cancellous Envelope at Month 3</title>
          <description>Change in dynamic histomorphometry indices was assessed in the cancellous envelope. BFR/BS was reported as cubic millimeter/square millimeter/year (mm^3/mm^2/year).</description>
          <population>The Bone-Biopsy Population included all participants who received an evaluable biopsy (defined as a biopsy sample that can be analyzed in the laboratory). Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
          <units>mm^3/mm^2/year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.011" spread="0.0076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.034" spread="0.0245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Procollagen Type I N-terminal Propeptide (s-P1NP) From Baseline at Month 1 and Month 3</title>
        <description>Blood samples were taken to measure efficacy related markers of bone metabolism at Day 1, Month 1, and Month 3.</description>
        <time_frame>Baseline (Day 1), Months 1 and 3</time_frame>
        <population>The Bone-Biopsy Population included all enrolled participants who received an evaluable biopsy (defined as a biopsy sample that can be analyzed in the laboratory). Here, 'Number Analyzed' signifies participants evaluable for the specified categories.</population>
        <group_list>
          <group group_id="O1">
            <title>Abaloparatide</title>
            <description>Participants self-administered a single daily dose of 80 µg of abaloparatide SC during the treatment period. Participants were instructed to use a new injection pen after each 30-day period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Procollagen Type I N-terminal Propeptide (s-P1NP) From Baseline at Month 1 and Month 3</title>
          <description>Blood samples were taken to measure efficacy related markers of bone metabolism at Day 1, Month 1, and Month 3.</description>
          <population>The Bone-Biopsy Population included all enrolled participants who received an evaluable biopsy (defined as a biopsy sample that can be analyzed in the laboratory). Here, 'Number Analyzed' signifies participants evaluable for the specified categories.</population>
          <units>nanograms (ng)/milliliter (mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.990" lower_limit="38.430" upper_limit="79.160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.155" lower_limit="62.810" upper_limit="242.240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.130" lower_limit="53.420" upper_limit="236.980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Carboxy-Terminal Cross-Linking Telopeptide of Type I Collagen (s-CTX) From Baseline at Month 1 and Month 3</title>
        <description>Blood samples were taken to measure efficacy-related markers of bone metabolism at Day 1, Month 1, and Month 3.</description>
        <time_frame>Baseline (Day 1), Months 1 and 3</time_frame>
        <population>The Bone-Biopsy Population included all enrolled participants who received an evaluable biopsy (defined as a biopsy sample that can be analyzed in the laboratory). Here, 'Number Analyzed' signifies participants evaluable for the specified categories.</population>
        <group_list>
          <group group_id="O1">
            <title>Abaloparatide</title>
            <description>Participants self-administered a single daily dose of 80 µg of abaloparatide SC during the treatment period. Participants were instructed to use a new injection pen after each 30-day period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Carboxy-Terminal Cross-Linking Telopeptide of Type I Collagen (s-CTX) From Baseline at Month 1 and Month 3</title>
          <description>Blood samples were taken to measure efficacy-related markers of bone metabolism at Day 1, Month 1, and Month 3.</description>
          <population>The Bone-Biopsy Population included all enrolled participants who received an evaluable biopsy (defined as a biopsy sample that can be analyzed in the laboratory). Here, 'Number Analyzed' signifies participants evaluable for the specified categories.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.460" lower_limit="0.308" upper_limit="0.549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.052" lower_limit="-0.109" upper_limit="0.174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.311" lower_limit="0.079" upper_limit="0.694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline (Day 1) up to Month 4 (main study) and Month 7 (sub-study)</time_frame>
      <desc>The Safety Population included all enrolled participants who received at least one dose of abaloparatide.</desc>
      <group_list>
        <group group_id="E1">
          <title>Abaloparatide</title>
          <description>Participants self-administered a single daily dose of 80 µg of abaloparatide SC during the treatment period. Participants were instructed to use a new injection pen after each 30-day period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Results may not be published prior to the Study Report completion. Investigators may publish results, providing a manuscript to the Sponsor =/&gt; 30 days prior to its submission to a publisher. Sponsor will provide manuscript to Investigators =/&gt; 30 days prior to its submission. Investigator shall comply with Sponsor's policy, withholding publication for an additional 60 days to permit the Sponsor to obtain patent or other proprietary rights protection, if deemed necessary.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Director, Clinical Operations</name_or_title>
      <organization>Radius Health, Inc.</organization>
      <phone>(617) 551-4000</phone>
      <email>info@radiuspharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

